Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody

In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from single B cells of the COVID-19–recovered individuals in India who experienced ancestral Wuhan strain (WA.1) of SARS-CoV-2 during early stages of the pandemic, we found a receptor binding domain (RBD)–specific m...

Full description

Saved in:
Bibliographic Details
Published inScience advances Vol. 8; no. 40; p. eadd2032
Main Authors Kumar, Sanjeev, Patel, Anamika, Lai, Lilin, Chakravarthy, Chennareddy, Valanparambil, Rajesh, Reddy, Elluri Seetharami, Gottimukkala, Kamalvishnu, Davis-Gardner, Meredith E., Edara, Venkata Viswanadh, Linderman, Susanne, Nayak, Kaustuv, Dixit, Kritika, Sharma, Pragati, Bajpai, Prashant, Singh, Vanshika, Frank, Filipp, Cheedarla, Narayanaiah, Verkerke, Hans P., Neish, Andrew S., Roback, John D., Mantus, Grace, Goel, Pawan Kumar, Rahi, Manju, Davis, Carl W., Wrammert, Jens, Godbole, Sucheta, Henry, Amy R., Douek, Daniel C., Suthar, Mehul S., Ahmed, Rafi, Ortlund, Eric, Sharma, Amit, Murali-Krishna, Kaja, Chandele, Anmol
Format Journal Article
LanguageEnglish
Published United States American Association for the Advancement of Science 07.10.2022
Subjects
Angiotensin-Converting Enzyme 2
Antibodies, Monoclonal - chemistry
Antibodies, Viral
Biomedicine and Life Sciences
Coronavirus
COVID-19
Epitopes
Humans
Neutralization Tests
SARS-CoV-2 - genetics
SciAdv r-articles
Spike Glycoprotein, Coronavirus
Online AccessGet full text

Cover

Abstract In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from single B cells of the COVID-19–recovered individuals in India who experienced ancestral Wuhan strain (WA.1) of SARS-CoV-2 during early stages of the pandemic, we found a receptor binding domain (RBD)–specific mAb 002-S21F2 that has rare gene usage and potently neutralized live viral isolates of SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta, and Omicron sublineages (BA.1, BA.2, BA.2.12.1, BA.4, and BA.5) with IC 50 ranging from 0.02 to 0.13 μg/ml. Structural studies of 002-S21F2 in complex with spike trimers of Omicron and WA.1 showed that it targets a conformationally conserved epitope on the outer face of RBD (class 3 surface) outside the ACE2-binding motif, thereby providing a mechanistic insights for its broad neutralization activity. The discovery of 002-S21F2 and the broadly neutralizing epitope it targets have timely implications for developing a broad range of therapeutic and vaccine interventions against SARS-CoV-2 variants including Omicron sublineages. A rare human monoclonal antibody neutralizes all SARS-CoV-2 Omicron variants by targeting a conserved epitope on the RBD.
AbstractList In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from single B cells of the COVID-19-recovered individuals in India who experienced ancestral Wuhan strain (WA.1) of SARS-CoV-2 during early stages of the pandemic, we found a receptor binding domain (RBD)-specific mAb 002-S21F2 that has rare gene usage and potently neutralized live viral isolates of SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta, and Omicron sublineages (BA.1, BA.2, BA.2.12.1, BA.4, and BA.5) with IC50 ranging from 0.02 to 0.13 μg/ml. Structural studies of 002-S21F2 in complex with spike trimers of Omicron and WA.1 showed that it targets a conformationally conserved epitope on the outer face of RBD (class 3 surface) outside the ACE2-binding motif, thereby providing a mechanistic insights for its broad neutralization activity. The discovery of 002-S21F2 and the broadly neutralizing epitope it targets have timely implications for developing a broad range of therapeutic and vaccine interventions against SARS-CoV-2 variants including Omicron sublineages.In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from single B cells of the COVID-19-recovered individuals in India who experienced ancestral Wuhan strain (WA.1) of SARS-CoV-2 during early stages of the pandemic, we found a receptor binding domain (RBD)-specific mAb 002-S21F2 that has rare gene usage and potently neutralized live viral isolates of SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta, and Omicron sublineages (BA.1, BA.2, BA.2.12.1, BA.4, and BA.5) with IC50 ranging from 0.02 to 0.13 μg/ml. Structural studies of 002-S21F2 in complex with spike trimers of Omicron and WA.1 showed that it targets a conformationally conserved epitope on the outer face of RBD (class 3 surface) outside the ACE2-binding motif, thereby providing a mechanistic insights for its broad neutralization activity. The discovery of 002-S21F2 and the broadly neutralizing epitope it targets have timely implications for developing a broad range of therapeutic and vaccine interventions against SARS-CoV-2 variants including Omicron sublineages.
In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from single B cells of the COVID-19–recovered individuals in India who experienced ancestral Wuhan strain (WA.1) of SARS-CoV-2 during early stages of the pandemic, we found a receptor binding domain (RBD)–specific mAb 002-S21F2 that has rare gene usage and potently neutralized live viral isolates of SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta, and Omicron sublineages (BA.1, BA.2, BA.2.12.1, BA.4, and BA.5) with IC 50 ranging from 0.02 to 0.13 μg/ml. Structural studies of 002-S21F2 in complex with spike trimers of Omicron and WA.1 showed that it targets a conformationally conserved epitope on the outer face of RBD (class 3 surface) outside the ACE2-binding motif, thereby providing a mechanistic insights for its broad neutralization activity. The discovery of 002-S21F2 and the broadly neutralizing epitope it targets have timely implications for developing a broad range of therapeutic and vaccine interventions against SARS-CoV-2 variants including Omicron sublineages. A rare human monoclonal antibody neutralizes all SARS-CoV-2 Omicron variants by targeting a conserved epitope on the RBD.
In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from single B cells of the COVID-19-recovered individuals in India who experienced ancestral Wuhan strain (WA.1) of SARS-CoV-2 during early stages of the pandemic, we found a receptor binding domain (RBD)-specific mAb 002-S21F2 that has rare gene usage and potently neutralized live viral isolates of SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta, and Omicron sublineages (BA.1, BA.2, BA.2.12.1, BA.4, and BA.5) with IC ranging from 0.02 to 0.13 μg/ml. Structural studies of 002-S21F2 in complex with spike trimers of Omicron and WA.1 showed that it targets a conformationally conserved epitope on the outer face of RBD (class 3 surface) outside the ACE2-binding motif, thereby providing a mechanistic insights for its broad neutralization activity. The discovery of 002-S21F2 and the broadly neutralizing epitope it targets have timely implications for developing a broad range of therapeutic and vaccine interventions against SARS-CoV-2 variants including Omicron sublineages.
Author Edara, Venkata Viswanadh
Douek, Daniel C.
Godbole, Sucheta
Henry, Amy R.
Suthar, Mehul S.
Chandele, Anmol
Sharma, Amit
Lai, Lilin
Kumar, Sanjeev
Davis, Carl W.
Patel, Anamika
Neish, Andrew S.
Valanparambil, Rajesh
Linderman, Susanne
Nayak, Kaustuv
Rahi, Manju
Wrammert, Jens
Dixit, Kritika
Roback, John D.
Davis-Gardner, Meredith E.
Goel, Pawan Kumar
Cheedarla, Narayanaiah
Ahmed, Rafi
Murali-Krishna, Kaja
Singh, Vanshika
Verkerke, Hans P.
Chakravarthy, Chennareddy
Gottimukkala, Kamalvishnu
Frank, Filipp
Mantus, Grace
Bajpai, Prashant
Ortlund, Eric
Sharma, Pragati
Reddy, Elluri Seetharami
Author_xml – sequence: 1
  givenname: Sanjeev
  orcidid: 0000-0002-8181-3999
  surname: Kumar
  fullname: Kumar, Sanjeev
  organization: ICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India
– sequence: 2
  givenname: Anamika
  orcidid: 0000-0003-4760-9019
  surname: Patel
  fullname: Patel, Anamika
  organization: Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA
– sequence: 3
  givenname: Lilin
  surname: Lai
  fullname: Lai, Lilin
  organization: Department of Pediatrics, Emory University School of Medicine, Emory University Atlanta, GA 30322, USA., Department of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA
– sequence: 4
  givenname: Chennareddy
  orcidid: 0000-0002-3937-5788
  surname: Chakravarthy
  fullname: Chakravarthy, Chennareddy
  organization: Department of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA., Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA
– sequence: 5
  givenname: Rajesh
  surname: Valanparambil
  fullname: Valanparambil, Rajesh
  organization: Department of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA., Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA
– sequence: 6
  givenname: Elluri Seetharami
  surname: Reddy
  fullname: Reddy, Elluri Seetharami
  organization: ICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India., Kusuma School of Biological Sciences, Indian Institute of Technology, New Delhi-110 016, India
– sequence: 7
  givenname: Kamalvishnu
  surname: Gottimukkala
  fullname: Gottimukkala, Kamalvishnu
  organization: ICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India
– sequence: 8
  givenname: Meredith E.
  orcidid: 0000-0002-6133-3613
  surname: Davis-Gardner
  fullname: Davis-Gardner, Meredith E.
  organization: Department of Pediatrics, Emory University School of Medicine, Emory University Atlanta, GA 30322, USA
– sequence: 9
  givenname: Venkata Viswanadh
  orcidid: 0000-0001-9321-7839
  surname: Edara
  fullname: Edara, Venkata Viswanadh
  organization: Department of Pediatrics, Emory University School of Medicine, Emory University Atlanta, GA 30322, USA
– sequence: 10
  givenname: Susanne
  orcidid: 0000-0003-3297-3774
  surname: Linderman
  fullname: Linderman, Susanne
  organization: Department of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA., Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA
– sequence: 11
  givenname: Kaustuv
  orcidid: 0000-0002-7898-0294
  surname: Nayak
  fullname: Nayak, Kaustuv
  organization: ICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India
– sequence: 12
  givenname: Kritika
  orcidid: 0000-0002-7999-7274
  surname: Dixit
  fullname: Dixit, Kritika
  organization: ICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India
– sequence: 13
  givenname: Pragati
  orcidid: 0000-0002-7554-6230
  surname: Sharma
  fullname: Sharma, Pragati
  organization: ICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India
– sequence: 14
  givenname: Prashant
  orcidid: 0000-0002-8443-9787
  surname: Bajpai
  fullname: Bajpai, Prashant
  organization: ICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India
– sequence: 15
  givenname: Vanshika
  surname: Singh
  fullname: Singh, Vanshika
  organization: ICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India
– sequence: 16
  givenname: Filipp
  orcidid: 0000-0001-8680-2757
  surname: Frank
  fullname: Frank, Filipp
  organization: Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA
– sequence: 17
  givenname: Narayanaiah
  orcidid: 0000-0001-6072-4383
  surname: Cheedarla
  fullname: Cheedarla, Narayanaiah
  organization: Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
– sequence: 18
  givenname: Hans P.
  surname: Verkerke
  fullname: Verkerke, Hans P.
  organization: Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA., Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02215, USA
– sequence: 19
  givenname: Andrew S.
  orcidid: 0000-0002-7090-0237
  surname: Neish
  fullname: Neish, Andrew S.
  organization: Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
– sequence: 20
  givenname: John D.
  orcidid: 0000-0001-9952-2252
  surname: Roback
  fullname: Roback, John D.
  organization: Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
– sequence: 21
  givenname: Grace
  surname: Mantus
  fullname: Mantus, Grace
  organization: Department of Pediatrics, Emory University School of Medicine, Emory University Atlanta, GA 30322, USA., Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA
– sequence: 22
  givenname: Pawan Kumar
  surname: Goel
  fullname: Goel, Pawan Kumar
  organization: Shaheed Hasan Khan Mewat Government Medical College, Haryana, India
– sequence: 23
  givenname: Manju
  orcidid: 0000-0003-0932-0935
  surname: Rahi
  fullname: Rahi, Manju
  organization: Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research, New Delhi-110 029, India
– sequence: 24
  givenname: Carl W.
  orcidid: 0000-0002-6049-0684
  surname: Davis
  fullname: Davis, Carl W.
  organization: Department of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA., Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA
– sequence: 25
  givenname: Jens
  orcidid: 0000-0002-1733-4424
  surname: Wrammert
  fullname: Wrammert, Jens
  organization: Department of Pediatrics, Emory University School of Medicine, Emory University Atlanta, GA 30322, USA., Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA
– sequence: 26
  givenname: Sucheta
  surname: Godbole
  fullname: Godbole, Sucheta
  organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
– sequence: 27
  givenname: Amy R.
  surname: Henry
  fullname: Henry, Amy R.
  organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
– sequence: 28
  givenname: Daniel C.
  surname: Douek
  fullname: Douek, Daniel C.
  organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
– sequence: 29
  givenname: Mehul S.
  orcidid: 0000-0002-2686-8380
  surname: Suthar
  fullname: Suthar, Mehul S.
  organization: Department of Pediatrics, Emory University School of Medicine, Emory University Atlanta, GA 30322, USA., Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA
– sequence: 30
  givenname: Rafi
  orcidid: 0000-0002-9591-2621
  surname: Ahmed
  fullname: Ahmed, Rafi
  organization: Department of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA., Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA
– sequence: 31
  givenname: Eric
  orcidid: 0000-0001-8855-3029
  surname: Ortlund
  fullname: Ortlund, Eric
  organization: Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA
– sequence: 32
  givenname: Amit
  orcidid: 0000-0002-3305-0034
  surname: Sharma
  fullname: Sharma, Amit
  organization: ICMR-National Institute of Malaria Research, Dwarka, New Delhi-110 077, India., Structural Parasitology Group, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India
– sequence: 33
  givenname: Kaja
  orcidid: 0000-0002-6275-1710
  surname: Murali-Krishna
  fullname: Murali-Krishna, Kaja
  organization: ICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India., Department of Pediatrics, Emory University School of Medicine, Emory University Atlanta, GA 30322, USA., Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA
– sequence: 34
  givenname: Anmol
  orcidid: 0000-0002-5702-7170
  surname: Chandele
  fullname: Chandele, Anmol
  organization: ICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36197988$$D View this record in MEDLINE/PubMed
BookMark eNp1UUlvEzEYtVARLaVXjshHDp0wXse-IIWITapUiQBXy2N7UqOJXWxPpHDlj-M06YbUy-dP9lus916CoxCDA-A1amcIYf4uG6_tZqatxS3Bz8AJJh1rMKPi6MF-DM5y_tW2LaKcMyRfgGPCkeykECfg77KkyZQp6RH6kP3qqmQ4xASDm0q99H908THAOMDLtTeprhudvA4V9mE-Q-e7iW8mPYc62N3GYL-FGvYpajtu76V8WMHl_NuyWcSfDa7o4vtot6_A80GP2Z0dzlPw49PH74svzcXl56-L-UVjKOOl4R2yzmEtBOEWM4J7aZzmUjJnWkqc5J1AVghmyICE66QkpG-FJMZQTKUhp-D9Xvd66tfOGhd231LXya912qqovXr8EvyVWsWNkoxQKnEVeHsQSPH35HJRa5-NG0cdXJyywh3GBOGOowp989DrzuQ2-Qqge0DNNOfkBmV8ucm6WvtRoVbtOlb7jtWh40qb_Ue7VX6C8A_TC6pr
CitedBy_id crossref_primary_10_1038_s42003_024_06951_7
crossref_primary_10_3389_fimmu_2023_1211558
crossref_primary_10_1039_D3CP05893J
crossref_primary_10_1016_j_ijbiomac_2023_125997
crossref_primary_10_1038_s41467_023_37051_5
crossref_primary_10_3390_bios13020167
crossref_primary_10_1016_j_isci_2023_107579
crossref_primary_10_1021_acsomega_2c07933
crossref_primary_10_3390_ijms24043774
crossref_primary_10_1007_s10822_023_00534_0
crossref_primary_10_1016_j_jbc_2024_108072
crossref_primary_10_1016_j_isci_2023_106955
crossref_primary_10_1016_j_isci_2023_107967
crossref_primary_10_3389_fimmu_2022_1061686
crossref_primary_10_1016_j_str_2023_06_005
crossref_primary_10_3390_vaccines12020120
crossref_primary_10_1016_j_ijbiomac_2025_141417
crossref_primary_10_1016_j_str_2023_04_010
crossref_primary_10_1016_j_celrep_2023_113150
crossref_primary_10_1016_j_coviro_2023_101332
crossref_primary_10_1073_pnas_2412787122
crossref_primary_10_1128_jvi_00286_23
crossref_primary_10_3390_v16060900
crossref_primary_10_1128_jvi_01137_23
Cites_doi 10.1016/j.immuni.2016.08.016
10.1038/s41586-020-2852-1
10.1016/j.jsb.2012.09.006
10.1126/sciimmunol.abp9312
10.1126/science.aax4380
10.1371/journal.ppat.1009885
10.1002/pro.3235
10.1126/science.abn8652
10.7554/eLife.61312
10.1038/s41586-022-04980-y
10.1101/2022.05.08.491108
10.1126/science.aad9195
10.1038/nmeth.4193
10.1038/s41586-022-04594-4
10.1093/bioinformatics/btaa739
10.1002/bmb.20966
10.1016/j.jmb.2007.05.022
10.1038/s41587-020-0631-z
10.1016/j.xcrm.2020.100040
10.1016/j.cell.2019.04.036
10.1038/nmeth.4169
10.1200/JCO.21.02986
10.1126/science.abn8897
10.1126/science.abh2315
10.1016/j.cell.2021.12.032
10.1371/journal.ppat.1009958
10.1107/S0907444910007493
10.1038/s41586-021-04389-z
10.3389/fcimb.2022.928279
10.1126/science.abm8143
10.1038/nsmb.3115
10.1038/s41591-021-01678-y
10.1016/j.cell.2020.02.058
10.1038/s41467-021-24435-8
10.1038/s41586-021-03819-2
10.1093/cid/ciac203
10.1016/j.xcrm.2022.100529
10.1016/j.cell.2022.02.023
10.1002/pro.3330
10.1016/j.immuni.2022.06.005
10.1016/j.celrep.2022.110812
10.1038/s41586-019-0879-y
10.1107/S0907444909052925
10.1093/nar/gkg085
10.1107/S2059798318002425
10.1016/j.virol.2021.02.002
10.1128/JVI.01495-18
ContentType Journal Article
Copyright Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). 2022 The Authors
Copyright_xml – notice: Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). 2022 The Authors
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1126/sciadv.add2032
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
DocumentTitleAlternate A broadly neutralizing SARS-CoV-2 Omicron antibody
EISSN 2375-2548
ExternalDocumentID PMC9534492
36197988
10_1126_sciadv_add2032
Genre Journal Article
GrantInformation_xml – fundername: NIGMS NIH HHS
  grantid: T32 GM008169
– fundername: NIGMS NIH HHS
  grantid: T32 GM142617
– fundername: ;
  grantid: VIR/COVID- 19/02/2020/ECD-1
– fundername: ;
  grantid: P51 OD011132
– fundername: ;
  grantid: BT/PR30260/MED/15/194/2018
– fundername: ;
  grantid: BT/NBM099/02/18
– fundername: ;
  grantid: COVID-Catalyst-I3
– fundername: ;
  grantid: IA/E/18/1/504307
– fundername: ;
  grantid: HHSN272201400004C
GroupedDBID 53G
5VS
AAFWJ
AAYXX
ACGFS
ADAXU
ADBBV
ADPDF
AENVI
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BCGUY
BCNDV
BKF
CITATION
EBS
FRP
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
OVD
OVEED
RHI
RPM
TEORI
BBORY
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c456t-671dee2a8836d2532b9cea6995ec043e96781d885c3f18e79933b0893cc4249c3
IEDL.DBID M48
ISSN 2375-2548
IngestDate Thu Aug 21 18:39:25 EDT 2025
Fri Jul 11 14:12:14 EDT 2025
Thu Apr 03 07:05:10 EDT 2025
Tue Jul 01 03:11:41 EDT 2025
Thu Apr 24 23:05:52 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 40
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c456t-671dee2a8836d2532b9cea6995ec043e96781d885c3f18e79933b0893cc4249c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
ORCID 0000-0002-9591-2621
0000-0002-7554-6230
0000-0002-7999-7274
0000-0001-9952-2252
0000-0001-8680-2757
0000-0003-0932-0935
0000-0002-2686-8380
0000-0002-8181-3999
0000-0002-1733-4424
0000-0002-7898-0294
0000-0003-3297-3774
0000-0002-3305-0034
0000-0002-8443-9787
0000-0002-6133-3613
0000-0003-4760-9019
0000-0001-9321-7839
0000-0002-6049-0684
0000-0001-8855-3029
0000-0002-7090-0237
0000-0002-3937-5788
0000-0001-6072-4383
0000-0002-6275-1710
0000-0002-5702-7170
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1126/sciadv.add2032
PMID 36197988
PQID 2722312761
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9534492
proquest_miscellaneous_2722312761
pubmed_primary_36197988
crossref_citationtrail_10_1126_sciadv_add2032
crossref_primary_10_1126_sciadv_add2032
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-10-07
PublicationDateYYYYMMDD 2022-10-07
PublicationDate_xml – month: 10
  year: 2022
  text: 2022-10-07
  day: 07
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Science advances
PublicationTitleAlternate Sci Adv
PublicationYear 2022
Publisher American Association for the Advancement of Science
Publisher_xml – name: American Association for the Advancement of Science
References e_1_3_2_26_2
e_1_3_2_49_2
e_1_3_2_27_2
e_1_3_2_48_2
e_1_3_2_28_2
e_1_3_2_29_2
e_1_3_2_41_2
e_1_3_2_40_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_22_2
e_1_3_2_45_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_24_2
e_1_3_2_47_2
e_1_3_2_25_2
e_1_3_2_46_2
e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_18_2
e_1_3_2_39_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_32_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_2_2
e_1_3_2_14_2
e_1_3_2_35_2
References_xml – ident: e_1_3_2_28_2
  doi: 10.1016/j.immuni.2016.08.016
– ident: e_1_3_2_14_2
  doi: 10.1038/s41586-020-2852-1
– ident: e_1_3_2_38_2
  doi: 10.1016/j.jsb.2012.09.006
– ident: e_1_3_2_26_2
  doi: 10.1126/sciimmunol.abp9312
– ident: e_1_3_2_29_2
  doi: 10.1126/science.aax4380
– ident: e_1_3_2_3_2
  doi: 10.1371/journal.ppat.1009885
– ident: e_1_3_2_43_2
  doi: 10.1002/pro.3235
– ident: e_1_3_2_20_2
  doi: 10.1126/science.abn8652
– ident: e_1_3_2_5_2
  doi: 10.7554/eLife.61312
– ident: e_1_3_2_25_2
  doi: 10.1038/s41586-022-04980-y
– ident: e_1_3_2_23_2
  doi: 10.1101/2022.05.08.491108
– ident: e_1_3_2_27_2
  doi: 10.1126/science.aad9195
– ident: e_1_3_2_40_2
  doi: 10.1038/nmeth.4193
– ident: e_1_3_2_10_2
  doi: 10.1038/s41586-022-04594-4
– ident: e_1_3_2_22_2
  doi: 10.1093/bioinformatics/btaa739
– ident: e_1_3_2_49_2
  doi: 10.1002/bmb.20966
– ident: e_1_3_2_48_2
  doi: 10.1016/j.jmb.2007.05.022
– ident: e_1_3_2_35_2
  doi: 10.1038/s41587-020-0631-z
– ident: e_1_3_2_30_2
  doi: 10.1016/j.xcrm.2020.100040
– ident: e_1_3_2_31_2
  doi: 10.1016/j.cell.2019.04.036
– ident: e_1_3_2_39_2
  doi: 10.1038/nmeth.4169
– ident: e_1_3_2_36_2
  doi: 10.1200/JCO.21.02986
– ident: e_1_3_2_19_2
  doi: 10.1126/science.abn8897
– ident: e_1_3_2_13_2
  doi: 10.1126/science.abh2315
– ident: e_1_3_2_15_2
  doi: 10.1016/j.cell.2021.12.032
– ident: e_1_3_2_37_2
  doi: 10.1371/journal.ppat.1009958
– ident: e_1_3_2_45_2
  doi: 10.1107/S0907444910007493
– ident: e_1_3_2_9_2
  doi: 10.1038/s41586-021-04389-z
– ident: e_1_3_2_4_2
  doi: 10.3389/fcimb.2022.928279
– ident: e_1_3_2_24_2
  doi: 10.1126/science.abm8143
– ident: e_1_3_2_46_2
  doi: 10.1038/nsmb.3115
– ident: e_1_3_2_8_2
  doi: 10.1038/s41591-021-01678-y
– ident: e_1_3_2_12_2
  doi: 10.1016/j.cell.2020.02.058
– ident: e_1_3_2_21_2
  doi: 10.1038/s41467-021-24435-8
– ident: e_1_3_2_42_2
  doi: 10.1038/s41586-021-03819-2
– ident: e_1_3_2_6_2
  doi: 10.1093/cid/ciac203
– ident: e_1_3_2_7_2
  doi: 10.1016/j.xcrm.2022.100529
– ident: e_1_3_2_32_2
  doi: 10.1016/j.cell.2022.02.023
– ident: e_1_3_2_47_2
  doi: 10.1002/pro.3330
– ident: e_1_3_2_11_2
  doi: 10.1016/j.immuni.2022.06.005
– ident: e_1_3_2_18_2
  doi: 10.1016/j.celrep.2022.110812
– ident: e_1_3_2_17_2
  doi: 10.1038/s41586-019-0879-y
– ident: e_1_3_2_41_2
  doi: 10.1107/S0907444909052925
– ident: e_1_3_2_34_2
  doi: 10.1093/nar/gkg085
– ident: e_1_3_2_44_2
  doi: 10.1107/S2059798318002425
– ident: e_1_3_2_2_2
– ident: e_1_3_2_16_2
  doi: 10.1016/j.virol.2021.02.002
– ident: e_1_3_2_33_2
  doi: 10.1128/JVI.01495-18
SSID ssj0001466519
Score 2.3554657
Snippet In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from single B cells of the COVID-19–recovered individuals in India who...
In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from single B cells of the COVID-19-recovered individuals in India who...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage eadd2032
SubjectTerms Angiotensin-Converting Enzyme 2
Antibodies, Monoclonal - chemistry
Antibodies, Viral
Biomedicine and Life Sciences
Coronavirus
COVID-19
Epitopes
Humans
Neutralization Tests
SARS-CoV-2 - genetics
SciAdv r-articles
Spike Glycoprotein, Coronavirus
Title Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody
URI https://www.ncbi.nlm.nih.gov/pubmed/36197988
https://www.proquest.com/docview/2722312761
https://pubmed.ncbi.nlm.nih.gov/PMC9534492
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1baxQxFA5aQfpSrNdVWyIIKjTLTJLJ5UHKWqxFUMF1Zd-G3AYXthntbIv77B_3ZGZ227X2JQzMmTzky-F8J3PyHYReZtqyIKwilZGGgCcyYgwXxEuVmSCDqnxbbfFZnEz4x2kxvax_6hew-W9ql_pJTc7mw9-_lofg8G-vXIAx_mIInpragd9GdyAqydTN4FNP9dvzFi4EsJVet_H6Z9voLoNkIsl3bYaoa7zz3_LJK_Ho-B7a6YkkHnXI76JbId5Hu72rNvh1ryf95gH6M241YpO-Bp7FJmXjDQauimM4b885upuYuK7wl9NUnxfxBWTQqUAGvxsN84M00nbkB9hEn54KbJfYYHtWGz9fXk4FkRCPR1_H5Kj-TihYL2a29suHaHL8_tvRCel7LxAHlGpBhMx9CNQoxYSnBaNWu2CE1kVwGWdBQ5DLvVKFY1WuggSaw2wG5Mc5DhmdY4_QVqxjeIKwF4C4qiqw05xSZ6zPDHWOagnkgsoBIqvlLl0vTJ76Y8zLNkGhouyQKnukBujV2v5nJ8lxo-WLFXoleE36FWJiqM-bkkqgRTmVIh-gxx2a67lW22CA5AbOa4OkyL35Js5-tMrcumCca_r0xjmfoW2a7k-kCgT5HG0B_mEPWM3C7renATB-mOb77db9C4C0-Z0
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Structural+insights+for+neutralization+of+Omicron+variants+BA.1%2C+BA.2%2C+BA.4%2C+and+BA.5+by+a+broadly+neutralizing+SARS-CoV-2+antibody&rft.jtitle=Science+advances&rft.au=Kumar%2C+Sanjeev&rft.au=Patel%2C+Anamika&rft.au=Lai%2C+Lilin&rft.au=Chakravarthy%2C+Chennareddy&rft.date=2022-10-07&rft.eissn=2375-2548&rft.volume=8&rft.issue=40&rft.spage=eadd2032&rft_id=info:doi/10.1126%2Fsciadv.add2032&rft_id=info%3Apmid%2F36197988&rft.externalDocID=36197988
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2375-2548&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2375-2548&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2375-2548&client=summon